FDA Should Revise EUA Process for Tests Based on COVID-19 Lessons, OIG Says
- September 23, 2022
The Food and Drug Administration (FDA) should make changes to its Emergency Use Authorization (EUA) process based on insights from the COVID-19 pandemic to better prepare for future infectious disease outbreaks, the Department of Health and Human Services Office of Inspector General (OIG) said in a report released September 21.
ARTICLE TAGS
You must be logged in to access this content.